BIT Capital GmbH Takes Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Key Points

• BIT Capital GmbH has invested approximately $264,000 in Kiniksa Pharmaceuticals International by acquiring 11,878 shares in the first quarter.
• Kiniksa's stock recently traded up 5.7% to $31.98, with a market cap of $2.33 billion and a year high of $32.15.
• Analysts have raised target prices for Kiniksa Pharmaceuticals, with Wells Fargo increasing its target from $30.00 to $42.00 and giving an "overweight" rating.

BIT Capital GmbH acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 11,878 shares of the company's stock, valued at approximately $264,000.

A number of other hedge funds have also made changes to their positions in the company. Braidwell LP increased its position in shares of Kiniksa Pharmaceuticals International by 19.3% during the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after purchasing an additional 557,934 shares in the last quarter. Nuveen Asset Management LLC increased its position in shares of Kiniksa Pharmaceuticals International by 7.3% during the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after purchasing an additional 54,361 shares in the last quarter. Millennium Management LLC increased its position in shares of Kiniksa Pharmaceuticals International by 50.9% during the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company's stock worth $15,422,000 after purchasing an additional 263,146 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Kiniksa Pharmaceuticals International by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock worth $15,262,000 after purchasing an additional 29,300 shares in the last quarter. Finally, Parkman Healthcare Partners LLC increased its position in shares of Kiniksa Pharmaceuticals International by 1.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company's stock worth $15,141,000 after purchasing an additional 10,209 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Jefferies Financial Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Finally, Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $41.17.

Insider Activity

In other news, COO Eben Tessari sold 45,042 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $30.51, for a total value of $1,374,231.42. Following the completion of the transaction, the chief operating officer owned 72,363 shares in the company, valued at $2,207,795.13. This represents a 38.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ross Moat sold 27,594 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total transaction of $800,777.88. Following the completion of the transaction, the insider owned 9,415 shares of the company's stock, valued at $273,223.30. This trade represents a 74.56% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 314,709 shares of company stock valued at $9,013,851. 53.48% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals International Trading Up 0.5%

Shares of NASDAQ:KNSA traded up $0.17 during trading on Tuesday, hitting $33.12. 370,697 shares of the company's stock were exchanged, compared to its average volume of 696,801. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $33.98. The firm has a 50-day moving average price of $28.50 and a two-hundred day moving average price of $24.25. The firm has a market cap of $2.42 billion, a P/E ratio of 828.08 and a beta of 0.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. As a group, research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.